Christian Grommes, MD
Memorial Sloan Kettering Cancer Center · Memorial SloanKettering Cancer Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Christian Grommes, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 07:27 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT07082868 · A Study of Epcoritamab and Ibrutinib in People With Central Nervous System Lymphoma (CNSL)Memorial Sloan Kettering Cancer Center · recruiting · Primary Central Nervous System Lymphoma (PCNSL), Primary Central Nervous System Lymphoma, Relapsed Primary Central Nervous System Lymphoma · principal investigator
- Ph2NCT04401774 · Nivolumab Maintenance in Newly Diagnosed PCNSL With Persistent CSF Circulating Tumor DNA After Completion of First-Line ChemotherapyMemorial Sloan Kettering Cancer Center · completed · Primary Central Nervous System Lymphoma (PCNSL) · principal investigator
- Ph2NCT03743662 · Nivolumab With Radiation Therapy and Bevacizumab for Recurrent MGMT Methylated GlioblastomaMemorial Sloan Kettering Cancer Center · active not recruiting · Glioblastoma · principal investigator
- Ph1NCT03703167 · Ibrutinib With Rituximab and Lenalidomide for Patients With Recurrent/Refractory Primary or Secondary Central Nervous System Lymphoma (PCNSL/SCNSL)Memorial Sloan Kettering Cancer Center · completed · Primary Central Nervous System Lymphoma (PCNSL), Secondary Central Nervous System Lymphoma (SCNSL) · principal investigator
- Ph1/Ph2NCT03581942 · Copanlisib With Ibrutinib for Patients With Recurrent/ Refractory Primary Central Nervous System Lymphoma (PCNSL)Memorial Sloan Kettering Cancer Center · completed · Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) · principal investigator
- Ph1/Ph2NCT02315326 · Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Newly Diagnosed or Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL)Memorial Sloan Kettering Cancer Center · completed · Adult Patients With Newly Diagnosed or Relapsed or Refractory Primary Central Nervous System Lymphoma (PCNSL), Or Relapsed or Refractory Secondary Central Nervous System Lymphoma (SCNSL) · principal investigator
- Ph2NCT02301364 · Buparlisib (BKM120) In Patients With Recurrent/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Recurrent/Refractory Secondary Central Nervous System Lymphoma (SCNSL)Memorial Sloan Kettering Cancer Center · completed · Lymphoma, Primary Central Nervous System Lymphoma, Recurrent/Refractory Secondary Central Nervous System Lymphoma · principal investigator
- Ph2NCT00596154 · Rituximab, Methotrexate, Procarbazine and Vincristine Followed by High-dose Chemotherapy With Autologous Stem-cell Rescue in Newly-diagnosed Primary CNS LymphomaMemorial Sloan Kettering Cancer Center · completed · CNS Lymphoma, CNS Brain Cancer, Non-Hodgkin's Lymphoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 07:27 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name.